MedTrace Logo

Acarbose and Secondary Prevention After Coronary Stenting

NCT00221156 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 300

Last updated 2009-06-25

No results posted yet for this study

Summary

The purpose of this study is to determine whether the intervention for newly diagnosed abnormal glucose tolerance after coronary stenting will improve the long-term clinical outcome.

Conditions

Interventions

DRUG

Acarbose

Sponsors & Collaborators

  • Institute of Biomedical Research and Innovation, Kobe, Hyogo, Japan

    collaborator OTHER

  • Kobe City General Hospital

    collaborator OTHER

  • Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan

    lead OTHER

Principal Investigators

  • Koichi Tamita, MD. · Division of Cardiology, Kobe General Hospital

  • Minako Katayama, MD · Division of Clinical Research Promotion, Institute of Biomedical Research and Innovation.

  • Yutaka Furukawa, MD · Division of Cardiology, Kobe General Hospital

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-05-31
Completion
2009-04-30

Countries

  • Japan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00221156 on ClinicalTrials.gov